National HIV and HCV Screening Rates for Hospitalized People Who Use Drugs Are Suboptimal and Heterogeneous across 11 U.S. Hospitals

Leo Knudsen Westgard, Taisuke Sato,William S Bradford,Ellen F Eaton, Finlay Pilcher,Andrew J Hale,Devika Singh,Marlene Martin,Ayesha A Appa,Jaimie P Meyer, Melissa B Weimer, Lydia A Barakat,Uriel R Felsen,Matthew J Akiyama,Jessica P Ridgway, Emily D Grussing,Kinna Thakarar, Amy White, John Mutelayi,Martin Krsak,Brian T Montague,Ank Nijhawan, Harini Balakrishnan,Laura R Marks, Alysse G Wurcel

Open Forum Infectious Diseases(2024)

引用 0|浏览5
暂无评分
摘要
Abstract To end the HIV and HCV epidemics, people who use drugs (PWUD) need more opportunities for testing. While inpatient hospitalizations are an essential opportunity to test PWUD for HIV and HCV, there is limited research on rates of inpatient testing for HIV and HCV among PWUD. Eleven hospital sites were included in the study. Each site created a cohort of inpatient encounters associated with injection drug use. From these cohorts, we collected data on HCV and HIV testing rates and HIV testing consent policies from 65,276 PWUD hospitalizations. Hospitals had average screening rates of 40% for HIV and 32% for HCV, with widespread heterogeneity in screening rates across facilities. State consent laws and opt-out testing policies were not associated with statistically significant differences in HIV screening rates. On average, hospitals that reflexed HCV viral load testing on HCV antibody testing did not have statistically significant differences in HCV viral load testing rates. We found suboptimal testing rates during inpatient encounters for PWUD. As treatment (HIV) and cure (HCV) are necessary to end these epidemics, understanding and overcoming barriers to testing need to be prioritized.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要